125I 放射性粒子治疗原发性肝癌的疗效研究

目的：评价125I放射性粒子植入治疗原发性肝癌的临床疗效。 方法：回顾性分析2009年6月—2012年8月84例接受125I放射性粒子植入治疗肝癌患者的临床资料。 结果：84例患者共植入粒子3 630粒，其中肿瘤≤3.5 cm患者平均17粒；肿瘤>3.5 cm患者平均46粒，所有患者均一次性植入成功。患者植入治疗后疼痛明显减轻或消失，达完全缓解（CR）者为40例，部分缓解（PR）36例，疾病稳定（SD）8例，总有效率（CR+PR）为90.5%。术后随访3~45个月，患者平均生存率期为16.5个月，1、2年生存率分别为64.3%、31.0%。 结论：125I放射性粒子瘤内植入治疗原发性肝癌疗效确切，可作为治疗难治性、复发性、转移性肝癌的一种重要选择。

125I radioactive seed implantation for primary liver cancer

Objective: To evaluate the clinical efficacy of 125I radioactive seed implantation in treatment of primary liver cancer. Methods: The clinical data of 84 liver cancer patients undergoing 125I radioactive seed implantation from June 2009 to August 2012 were retrospectively analyzed. Results: A total of 3 630 seeds were implanted in the 84 patients, with an average of 17 seeds for tumor size equal to or less than 35 cm and an average of 46 seeds for tumor size larger than 35 cm, and all patients were successfully implanted in one session. After implantation, the pain of the patients was relieved or disappeared, complete response (CR) was achieved in 40 cases, partial response (PR) was obtained in 36 cases, stable disease (SD) was seen in 8 cases, and the overall effective rate (CR+PR) was 90.5%. Postoperative follow-up ranged from 3 to 45 months, the average survival time of the patients was 16.5 months, and their 1- and 2-year survival rate was 64.3% and 31.0%, respectively. Conclusion: Intratumoral 125I radioactive seed implantation has demonstrable efficacy, and can be used as an alternative treatment modality for refractory, recurrent or metastatic liver cancer.